Akero Therapeutics (AKRO)
(Real Time Quote from BATS)
$28.05 USD
0.00 (0.00%)
Updated Sep 25, 2024 03:43 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Akero Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 550 | 351 | 188 | 268 | 136 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 10 | 4 | 5 | 3 | 2 |
Total Current Assets | 560 | 355 | 194 | 271 | 138 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 19 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 580 | 357 | 196 | 273 | 138 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 8 | 7 | 3 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 11 | 18 | 10 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 19 | 19 | 25 | 13 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 25 | 10 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 45 | 30 | 26 | 15 | 9 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,109 | 749 | 479 | 468 | 259 |
Retained Earnings | -574 | -422 | -310 | -210 | -130 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 535 | 327 | 169 | 259 | 129 |
Total Liabilities & Shareholder's Equity | 580 | 357 | 196 | 273 | 138 |
Total Common Equity | 535 | 327 | 169 | 259 | 129 |
Shares Outstanding | 55.70 | 46.70 | 34.80 | 34.70 | 28.50 |
Book Value Per Share | 9.61 | 6.99 | 4.86 | 7.46 | 4.52 |
Fiscal Year End for Akero Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 760 | 904 | 550 | 555 | 639 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 16 | 8 | 10 | 21 | 4 |
Total Current Assets | 776 | 911 | 560 | 576 | 643 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 88 | 0 | 19 | 58 | 19 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 865 | 912 | 580 | 635 | 664 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 2 | 0 |
Accounts Payable | 15 | 14 | 7 | 11 | 10 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 17 | 16 | 12 | 15 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 31 | 30 | 19 | 28 | 22 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 35 | 35 | 25 | 23 | 25 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 67 | 66 | 45 | 52 | 47 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,482 | 1,474 | 1,109 | 1,103 | 1,096 |
Retained Earnings | -683 | -627 | -574 | -519 | -479 |
Other Equity | 0 | 0 | 0 | -1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 798 | 846 | 535 | 583 | 616 |
Total Liabilities & Shareholder's Equity | 865 | 912 | 580 | 635 | 664 |
Total Common Equity | 798 | 846 | 535 | 583 | 616 |
Shares Outstanding | 69.10 | 69.10 | 55.70 | 55.60 | 50.10 |
Book Value Per Share | 11.55 | 12.25 | 9.61 | 10.49 | 12.30 |